Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect Clinical Oncology j o u r n a l h o m e p a g e : w w w. c l i n i c a l o n c o l og y o nl i n e. n e t
Objective
The Covid‐19 pandemic led to challenging discussions between oncology clinicians and patients regarding additional risks posed by SARS‐CoV‐2 infection whilst receiving systemic anti‐cancer therapies (SACT). We assess the potential factors affecting discontinuation of adjuvant early breast cancer treatment during the pandemic.
Methods
Data were collected on all patients with early breast cancer undergoing adjuvant SACT, between 16 March and 17 April 2020 at a single UK cancer centre. Univariate binary logistic regression analysis was performed on variables including age, recurrence risk, Index of Multiple Deprivation decile, presence of physical comorbidities, modality of treatment (neoadjuvant or adjuvant), type of treatment (cytotoxic chemotherapy or monoclonal antibodies), percentage of cycles completed and availability of alternative treatments, with a binary dependent variable on treatment discontinuation.
Results
Sixty‐two patients with early breast cancer were identified: 18 receiving neoadjuvant and 44 adjuvant therapies. Median age was 57.5 years (range 31–75 years). Age (
P
= 0.02), percentage of treatment cycles completed (
P
= 0.014) and presence of alternative treatment options (
P
= 0.019) were significant factors for SACT discontinuation during the height of the Covid‐19 pandemic.
Conclusion
Factors affecting patients' decisions to discontinue SACT for early breast cancer during the Covid‐19 pandemic were elucidated, which may help identify patients requiring additional support.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.